English Korean Chinese
ホーム > 市場調査レポート > 医薬品 > 糖尿病 > 欧州における糖尿病治療市場
カテゴリ
医薬品 (4964)
OTC (153)
がん (943)
ドラッグデリバリー (185)
ワクチン (181)
感染症 (353)
規制環境 (132)
後発医薬品 (135)
骨疾患 (37)
処方薬 (158)
神経疾患 (174)
精神疾患 (89)
製薬企業関連 (531)
創薬 (1524)
糖尿病 (193)
動物用医薬 (17)
肥満症 (44)
市場調査レポート

欧州における糖尿病治療市場

European Diabetes Market

発行 Frost & Sullivan
出版日 2006年07月 商品コード 44980
ページ情報 英文  
価格
US$ 6,500 換算 ¥ 523,055 (税抜) Web Access (Regional License)
US$ 7,000 換算 ¥ 563,290 (税抜) Hard Copy & Web Access (Regional License)


原文目次

Abstract

This Frost & Sullivan research service titled European Diabetes Market provides an overview of current treatment options, drugs in pipeline, technological advancements in diabetes and revenues of the current delivery methods. The study also offers a complete analysis of key market drivers, restraints, and trends prevailing in the European market. In this research, Frost & Sullivan's expert analysts thoroughly examine the markets for insulin and OAD drugs.

Table of Contents

  • 1. Executive Summary
    • 1. Overview
      • 1. Executive Summary of the European Diabetes Market
  • 2. Introduction
    • 1. Disease State Overview
      • 1. Epidemiology
    • 2. Research Methodology
      • 1. Research Methodology for the European Diabetes Market
      • 2. Assumptions and Limitations
  • 3. Industry Challenges
    • 1. Challenges and Issues
      • 1. Challenges Facing the European Diabetes Market
  • 4. European Diabetes Market Analysis
    • 1. Total European Diabetes Market
      • 1. Market Overview and Segmentation
      • 2. Revenue Forecasts
    • 2. Insulin Market
      • 1. Market Overview
      • 2. Trends by Segment
      • 3. Market Engineering Measurements
      • 4. Market Drivers
      • a. Increasing Diabetic Population Puts More Pressure on Governments to Reduce Costs Incurred Because of Complications
      • b. Awareness of the Importance of Tight Glycaemic Control
      • c. Acceptance of Insulin Therapy among the Type 2 Diabetic Population
      • d. Introduction of More Convenient Forms of Insulin Delivery
      • 5. Market Restraints
      • a. Cost of Insulin Therapy
      • b. Resistance to Insulin Therapy
      • 6. Impact Probability Analysis
      • 7. Competitive Structure
      • 8. Market Share Analysis
      • 9. Revenue Forecasts
    • 3. Oral Anti-Diabetic (OAD) Drugs Market
      • 1. Market Overview
      • 2. Trends by Segment
      • 3. Market Engineering Measurements
      • 4. Market Drivers
      • 5. Market Restraints
      • 6. Impact Probability Analysis
      • 7. Competitive Structure
      • 8. Revenue Forecasts
    • 4. Diabetes Drugs in Pipeline
      • 1. Pipeline Analysis
  • 5. German Diabetes Market
    • 1. Market Engineering Research
      • 1. Market Overview
      • 2. Market Engineering Measurements
      • 3. Revenue Forecasts
  • 6. The United Kingdom Diabetes Market
    • 1. Market Engineering Research
      • 1. Market Overview
      • 2. Market Engineering Measurements
      • 3. Revenue Forecasts
  • 7. French Diabetes Market
    • 1. Market Engineering Research
      • 1. Market Overview
      • 2. Market Engineering Measurements
      • 3. Revenue Forecasts
  • 8. Italian Diabetes Market
    • 1. Market Engineering Research
      • 1. Market Overview
      • 2. Market Engineering Measurements
      • 3. Revenue Forecasts
  • 9. Spanish Diabetes Market
    • 1. Market Engineering Research
      • 1. Market Overview
      • 2. Market Engineering Measurements
      • 3. Revenue Forecasts
  • 10. Scandinavian Diabetes Market
    • 1. Market Engineering Research
      • 1. Market Overview
      • 2. Market Engineering Measurements
      • 3. Revenue Forecasts
  • 11. Benelux Diabetes Market
    • 1. Market Engineering Research
      • 1. Market Overview
      • 2. Market Engineering Measurements
      • 3. Revenue Forecasts
  • 12. Strategic Recommendations
    • 1. Market Engineering Recommendations
      • 1. Strategic Recommendations for the European Diabetes Market
  • 13. Database of Key Industry Participants
    • 1. Key Industry Participants
      • 1. Major Participants
  • 15. Appendix
    • 1. Decision Support Database
      • 1. Diabetes Incidence
      • 2. Diabetes Prevalence
      • 3. Diabetes Prevalence Percent
      • 4. Obesity Prevalence
      • 5. Total Healthcare Expenditure
Back to Top